Weis Sara, Shintani Satoshi, Weber Alberto, Kirchmair Rudolf, Wood Malcolm, Cravens Adrianna, McSharry Heather, Iwakura Atsushi, Yoon Young-Sup, Himes Nathan, Burstein Deborah, Doukas John, Soll Richard, Losordo Douglas, Cheresh David
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA.
J Clin Invest. 2004 Mar;113(6):885-94. doi: 10.1172/JCI20702.
Ischemia resulting from myocardial infarction (MI) promotes VEGF expression, leading to vascular permeability (VP) and edema, a process that we show here contributes to tissue injury throughout the ventricle. This permeability/edema can be assessed noninvasively by MRI and can be observed at the ultrastructural level as gaps between adjacent endothelial cells. Many of these gaps contain activated platelets adhering to exposed basement membrane, reducing vessel patency. Following MI, genetic or pharmacological blockade of Src preserves endothelial cell barrier function, suppressing VP and infarct volume, providing long-term improvement in cardiac function, fibrosis, and survival. To our surprise, an intravascular injection of VEGF into healthy animals, but not those deficient in Src, induced similar endothelial gaps, VP, platelet plugs, and some myocyte damage. Mechanistically, we show that quiescent blood vessels contain a complex involving Flk, VE-cadherin, and beta-catenin that is transiently disrupted by VEGF injection. Blockade of Src prevents disassociation of this complex with the same kinetics with which it prevents VEGF-mediated VP/edema. These findings define a molecular mechanism to account for the Src requirement in VEGF-mediated permeability and provide a basis for Src inhibition as a therapeutic option for patients with acute MI.
心肌梗死(MI)导致的缺血会促进血管内皮生长因子(VEGF)的表达,进而导致血管通透性(VP)增加和水肿,我们在此证明这一过程会导致整个心室的组织损伤。这种通透性/水肿可以通过磁共振成像(MRI)进行无创评估,并且在超微结构水平上可观察到相邻内皮细胞之间的间隙。许多这些间隙中含有粘附在暴露的基底膜上的活化血小板,从而降低血管通畅性。心肌梗死后,对Src进行基因或药物阻断可维持内皮细胞屏障功能,抑制血管通透性和梗死体积,长期改善心脏功能、纤维化和生存率。令我们惊讶的是,向健康动物而非Src缺乏的动物血管内注射VEGF会诱导出类似的内皮间隙、血管通透性、血小板栓子以及一些心肌细胞损伤。从机制上讲,我们发现静止血管中存在一种涉及Flk、血管内皮钙黏蛋白(VE-cadherin)和β-连环蛋白的复合物,VEGF注射会使其短暂破坏。对Src的阻断可防止该复合物解离,其动力学与防止VEGF介导的血管通透性/水肿相同。这些发现确定了一种分子机制来解释Src在VEGF介导的通透性中的需求,并为抑制Src作为急性心肌梗死患者的治疗选择提供了依据。